What is the equity of Arvinas this year?
Arvinas has equity of 660 M USD this year.
Arvinas Equity 2024
Arvinas Equity
660 M USD
Ticker
ARVN
ISIN
US04335A1051
WKN
A2N6VP
In 2024, Arvinas's equity was 660 M USD, a 16.83% increase from the 564.9 M USD equity in the previous year.
Arvinas Aktienanalyse
What does Arvinas do?
Arvinas Inc. is a biopharmaceutical company based in New Haven, Connecticut, USA. It was founded in 2013 by Dr. Craig Crews, who also serves as a scientific advisor to the company. The company's mission is to develop innovative therapies based on Proteolysis-Targeting Technology (PROTAC). This technology uses artificially engineered molecules to identify and mark specific proteins in the body, which are then degraded by the body's own enzymes. This approach can treat diseases caused by misfolded or overexpressed proteins. Arvinas' business model is to develop multiple drug candidates based on this platform. The company collaborates with leading academic institutions and biotechnology companies to identify targets that can be reached using PROTAC technology. Additionally, the company has a proprietary pipeline of drug candidates in various stages of clinical development. Arvinas operates in several therapeutic areas, including cancer, immunology, and metabolic disorders. Their drug candidates include ARV-110, a PROTAC targeting the androgen receptor protein (AR), which is a potential therapy for patients with resistant prostate cancer. Similarly, Arvinas' other drug candidates target specific proteins associated with certain diseases. Another drug from the company is ARV-471, an orally administered degrader targeting the estrogen receptor alpha (ERa), which plays a role in breast cancer. ARV-471 is a potential therapy for patients with rare subtypes of breast cancer. Arvinas also has partnerships in various areas of drug development. For example, in collaboration with Pfizer, they are developing ARV-411, a PROTAC targeting the menin-1 protein, which is involved in acute myeloid leukemia. Arvinas also has a partnership with Genentech, a subsidiary of Roche, for the use of PROTAC in the treatment of cancer. Overall, Arvinas is an innovative biopharmaceutical company based on Proteolysis-Targeting Technology, focusing on the development of comprehensive therapeutic approaches. With numerous partnerships and a diverse pipeline, the company is well-positioned to play a significant role in drug development. Arvinas ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Arvinas's Equity
Arvinas's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Arvinas's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Arvinas's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Arvinas's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Arvinas’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Arvinas stock
What was the equity of Arvinas compared to the previous year?
The equity of Arvinas has increased/decreased by 16.83% increased compared to the previous year.
What impact does a high equity have on investors of Arvinas?
A high equity is advantageous for investors of Arvinas as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Arvinas?
A low equity can be a risk for investors of Arvinas, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Arvinas affect the company?
An increase in equity of Arvinas can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Arvinas affect the company?
A reduction in equity of Arvinas can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Arvinas?
Some factors that can affect the equity of Arvinas include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Arvinas so important for investors?
The equity of Arvinas is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Arvinas take to change the equity?
To change equity, Arvinas can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Arvinas pay?
Over the past 12 months, Arvinas paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arvinas is expected to pay a dividend of 0 USD.
What is the dividend yield of Arvinas?
The current dividend yield of Arvinas is .
When does Arvinas pay dividends?
Arvinas pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Arvinas?
Arvinas paid dividends every year for the past 0 years.
What is the dividend of Arvinas?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Arvinas located?
Arvinas is assigned to the 'Health' sector.
Wann musste ich die Aktien von Arvinas kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Arvinas from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.
When did Arvinas pay the last dividend?
The last dividend was paid out on 10/6/2024.
What was the dividend of Arvinas in the year 2023?
In the year 2023, Arvinas distributed 0 USD as dividends.
In which currency does Arvinas pay out the dividend?
The dividends of Arvinas are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Arvinas
Our stock analysis for Arvinas Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arvinas Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
